Brief: Vicore Pharma Q4 Oper Loss Widens To SEK 13.7 Mln; Aims To List On Nasdaq Main List
March 15 (Reuters) - Vicore Pharma Holding AB VICOR.ST :
* Q4 OPERATING INCOME AMOUNTED TO 0.1 MSEK (0.3)
* Q4 OPERATING LOSS SEK 13.7 MILLION VERSUS LOSS SEK 9.1
MILLION
YEAR AGO
* GOAL FOR 2019: UP-LIST TO STOCKHOLM NASDAQ MAIN LIST
Source text for Eikon: ID:nWkr3GDqcL
Further company coverage: VICOR.ST
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Vicore Pharma Holding AB
See all newsBrief: Vicore Pharma Holding Q3 Net Revenues Amounted To Sek 0.6 Mln
Brief: Vicore Pharma Holding AB Phase 2B Aspire Trial Of Buloxibutid In Ipf Passes Pre-Planned Futility Analysis, On Track For Mid-2027 Topline Results
Brief: Vicore Pharma Q2 Operating Loss At SEK 150.1 Million
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:53 PM
Brief: Vicore Pharma Shares Start Trading In US On July 2